Effectiveness of second-generation antipsychotics: A naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone

BMC Psychiatry

Volumn 10, Issue , 2010, Pages

  Johnsen, Erik ^a   Kroken, Rune A ^a   Wentzel Larsen, Tore ^a   Jørgensen, Hugo A ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; AUTONOMIC NEUROPATHY; BODY MASS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GALACTORRHEA; GLOBAL ASSESSMENT OF FUNCTIONING SPLIT VERSION FUNCTIONS SCALE SCORE; HIP CIRCUMFERENCE; HUMAN; LENGTH OF STAY; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOLOGIC TEST; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DYSKINESIA; HOSPITAL READMISSION; HOSPITALIZATION; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; STATISTICS;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; FEMALE; GALACTORRHEA; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; PATIENT READMISSION; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SEVERITY OF ILLNESS INDEX; THIAZOLES; TREATMENT OUTCOME;

EID: 77951898891     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-10-26     Document Type: Article

References (44)

1. American Psychiatric Association Practice Guidelines for the Treatment of Patients with Schizophrenia. 2004, Arlington, VA: American Psychiatric Association, American Psychiatric Association.
2. Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Lieberman J, Schooler NR. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schiz Bull 2002, 28(1):5-16.
3. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller del D, McEvoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, Miller AL. The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007, 68(11):1751-1762. 10.4088/JCP.v68n1115, 18052569.
4. National Institute for Clinical Excellence Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal Guidance--No 2002, 43. Accessed November 02, 2008, National Institute for Clinical Excellence., http://www.nice.org.uk/
5. Jäger M, Frasch K, Weinmann S, Becker T. Treatment guidelines for non-schizophrenic psychotic disorders?. Psychiatr Prax 2007, 34:370-6. 10.1055/s-2007-970964, 17806003.
6. March JS, Silva SG, Compton S, Shapiro M, Califf R, Krishnan R. The case for practical clinical trials in psychiatry: The case for practical clinical trials in psychiatry. Am J Psychiatry 2005, 162:836-846. 10.1176/appi.ajp.162.5.836, 15863782.
7. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine. An exploratory analysis of head-to-head comparisons studies of second-generation antipsychotics. Am J Psychiatry 2006, 163:185-194. 10.1176/appi.ajp.163.2.185, 16449469.
8. Johnsen E, Jørgensen HA. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry 2008, 8:31. 10.1186/1471-244X-8-31, 2386457, 18439263.
9. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 355(12):1209-1223.
10. World Medical Association World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 2008, Accessed March 19, 2008, World Medical Association., http://www.wma.net/en/30publications/10policies/b3/index.html
11. Huf G, Coutinho ESF, Adams CE. Rapid tranquilisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine. BMJ 2007, 335:869. 10.1136/bmj.39339.448819.AE, 2043463, 17954515.
12. Huf G, Coutinho ESF, Adams CE, Borges RVS, Ferreira MAV, Silva FJF, Pereira AJCR, Abreu FM, Lugão SM, Santos MPCP, Gewandsznajder M, Mercadante VRP, Lange W, Dias CL. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ 2003, 327:708-13. 10.1136/bmj.327.7417.708, 200800, 14512476.
13. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
14. World Health Organization International Statistical Classification of Diseases and Related Health Problems. 10th Revision, Version for 2007. World Health Organization/German Institute of Medical Documentation and Information 1994, Accessed November 02, 2008, World Health Organization., http://www.who.int/classifications/apps/icd/icd10online/
15. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ, Okasha A, Singh B, Stein DJ, Ilie JP, Fleischhacker WW, Moeller HJ. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophrenia Res 2008, 100:20-38.
16. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophrenia Res 1990, 3:247-251.
17. Drake RE, Rosenberg SD, Mueser KT. Assessing substance use disorder in persons with severe mental illness. New Directions for Mental Health Services 1996, 70:3-17. 10.1002/yd.23319960203, 8754227.
18. Guy W. EDDEU Assessment Manual for Psychopharmacology - Revisited (DHHS publ NO ADM 91-338). 1976, Rockville, MD: US Department of Health and Human Services.
19. Karterud S, Pedersen G, Loevdahl H, Friis S. Global Assessment of Functioning--Split Version (S-GAF): Background and Scoring Manual. 1998, Oslo, Norway: Ullevaal University Hospital, Department of Psychiatry.
20. Lindström E, Lewander T, Malm U, Malt UF, Lublin H, Ahlfors UG. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry 2001, 55(Suppl 44):5-69.
21. Davis JM. Dose equivalence of the antipsychotic drugs. J Psychiatr Res 1974, 11:65-69. 10.1016/0022-3956(74)90071-5, 4156792.
22. Ronning M. The WHO Collaborating Centre for Drug Statistics Methodology. Established 1982, Accessed November 02, 2008., http://www.whocc.no/atcddd/
23. Higgins JPT, Green S, . editors Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 (updated September 2006). Accessesed 23rd April 2009, editors., http://www.cochrane.org/training/cochrane-handbook
24. R Development Core Team R A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, ISBN 3-900051-07-0. Accessed November 02, 2008, R Development Core Team R., http://www.r-project.org/
25. Pinheiro C, Bates DM. Mixed effects models in S and S-plus. 2000, New York: Springer.
26. Hedden SL, Woolson RF, Carter RE, Palesch Y, Ypadhyaya HP, Malcolm RJ. The impact of loss to follow-up on hypothesis tests of the treatment effect for several statistical methods in substance abuse trials. J Subst Abuse Treat 2009, 37:54-63. 10.1016/j.jsat.2008.09.011, 19008067.
27. Kahn R, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, Gheroghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 2008, 371:1085-97. 10.1016/S0140-6736(08)60486-9, 18374841.
28. Jerrel JM. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schiz Bull 2002, 28(4):589-605.
29. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RSE, Davis CE, Severe J, Hsiao JK. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006, 163:611-22. 10.1176/appi.ajp.163.4.611, 16585435.
30. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RSE, Miller AL, Belz JK. Effectiveness of Olanzapine, quetiapine, and risperidone ion patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study. Am J Psychiatry 2007, 164:415-27. 10.1176/appi.ajp.164.3.415, 17329466.
31. Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: Results from a randomized, open-label, 1-year trial. Value Health 2006, 9(2):77-89. 10.1111/j.1524-4733.2006.00083.x, 16626411.
32. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowsky SD. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007, 164:1050-60. 10.1176/appi.ajp.164.7.1050, 17606657.
33. Robinson DG, Woerner MG, Napolitano B, Patel RC, Sevy SM, Gunduz-Bruce H, Soto-Perello JM, Mendelowitz A, Khadivi A, Miller R, McCormack J, Lorell BS, Lesser ML, Schooler NR, Kane JM. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry 2006, 163:2096-2102. 10.1176/appi.ajp.163.12.2096, 17151160.
34. Crespo-Facorro B, Pérez-Iglesias R, Ramirez-Bonilla M, Martinéz-García O, LLorca J, Vásquez-Barquero JL. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry 2006, 67:1511-21. 10.4088/JCP.v67n1004, 17107241.
35. Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology 2006, 189:259-66. 10.1007/s00213-006-0564-3, 17058105.
36. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001, 23:1839-54. 10.1016/S0149-2918(00)89080-3, 11768836.
37. Ritchie CW, Chiu E, Harrigan S, Hall K, Hassett A, Macfarlane S, Mastwyk M, O'Connor DW, Opie J, Ames D. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psychiatry 2003, 18:432-40. 10.1002/gps.862, 12766921.
38. Ritchie CW, Chiu E, Harrigan S, Macfarlane S, Mastwyk M, Halliday G, Hustig H, Hall K, Hassett A, O'Connor DW, Opie J, Nagalingam V, Snowdon J, Ames D. A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. 2006, 21:171-9.
39. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RSE, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006, 163:2080-9. 10.1176/appi.ajp.163.12.2080, 17151158.
40. McCue RE, Waheed R, Urcuyo L, Orendain G, Joseph MD, Charles R, Hasan SM. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry 2006, 189:433-40. 10.1192/bjp.bp.105.019307, 17077434.
41. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. Cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 2006, 63:1079-87. 10.1001/archpsyc.63.10.1079, 17015810.
42. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Freeska E, Grabowski J, Graaeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA 2003, 290(20):2693-2702. 10.1001/jama.290.20.2693, 14645311.
43. Hofer A, Hummer M, Huber R, Kurz M, Walch T, Fleischhacker WW. Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol 2000, 20(6):699-702. 10.1097/00004714-200012000-00019, 11106145.
44. Robinson D, Woerner M, Pollack S, Lerner G. Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study. J Clin Psychopharmacol 1996, 16(2):170-176. 10.1097/00004714-199604000-00009, 8690832.